Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares gaining in premarket.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia financialpost.com
- FDA Approves Teva's Once-Monthly Injectable Olanzapine nasdaq.com
